Tag Archives: Dermatology

Almirall Achieves Robust Growth in Dermatology Sector, Expands Pipeline with Licensing Agreement

(IN BRIEF) Almirall, a leading biopharmaceutical company specializing in medical dermatology, has reported its full-year 2023 financial results, showcasing a 4% year-on-year growth in net sales driven by the strong performance of its European Dermatology business. The company’s total EBITDA … Read the full press release

Almirall Secures Global Rights for Promising Dermatological Treatment, NN-8828, Targeting IL-21

(IN BRIEF) Almirall S.A., a leading pharmaceutical company specializing in medical dermatology, has finalized an exclusive license agreement with Novo Nordisk for the development and commercialization of NN-8828, an IL-21 blocking monoclonal antibody. This innovative treatment holds potential for various … Read the full press release

Evonik to acquire company for innovative biomaterials for medical device technologies

Nanostructured biomaterial for wound dressings and dermatology to be integrated into Health Care business Evonik Venture Capital’s early investment in 2015 pays off Evonik aims to more than double the share of system solutions in Nutrition & Care by 2030 … Read the full press release

Barco announces the interface of Demetra digital skin imaging system with Modernizing Medicine’s electronic medical record (EMR)

(PRESS RELEASE) KORTRIJK, 23-Mar-2021 — /EuropaWire/ — Barco announces partnership with Modernizing Medicine for the interface of its Demetra digital skin imaging system with Modernizing Medicine’s electronic medical record (EMR). The interface aims to create a seamless workflow to reduce … Read the full press release

Almirall’s open innovation platform AlmirallShare announces two new partnerships aimed at finding new ways for the treatment of skin cancer and atopic dermatitis

These collaborations are in response to the calls for innovation via AlmirallShare, the open innovation platform of Almirall and aim to identify new biosignatures and treatments for skin cancer and atopic dermatitis AlmirallShare is responsible for 50% of the private-public … Read the full press release

Henkel closes epiCS® Skin Model Technology acquisition from SkinInVitro GmbH

Attractive portfolio with strong and successful models of the human skin Global dissemination of regulatory approved alternative test methods Important step towards the worldwide use and distribution of alternative test methods (PRESS RELEASE) DÜSSELDORF, 3-Nov-2020 — /EuropaWire/ — Henkel (ETR: … Read the full press release

First non-melanoma skin cancer patients treated with the Rhenium-SCT® in Germany

The first Rhenium-SCT® treatment was accomplished by the interregional professional association for nuclear medicine in Hanau (PRESS RELEASE) HANAU, Germany, 4-Oct-2019 — /EuropaWire/ — OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), … Read the full press release

OncoBeta® chosen as a 2019 Red Herring North America Top 100 Winner

New recognition of OncoBeta’s success in developing and providing an innovative therapy for non-melanoma skin cancer patients. (PRESS RELEASE) Pasadena, CA, U.S.A., 5-Jul-2019 — /EuropaWire/ — OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin … Read the full press release

Rhenium-SCT® (SCT= Skin Cancer Therapy) now being offered in Hanau, Germany

The interregional professional association for nuclear medicine in Hanau is the first treatment center in Germany offering Rhenium-SCT® for the treatment of non-melanoma skin cancer (PRESS RELEASE) GARCHING N. MUNICH, Germany, 13-May-2019 — /EuropaWire/ — OncoBeta® GmbH, a commercial stage … Read the full press release

New Study Reconfirms Effectiveness and Safety of Fotona Dynamis Laser Treatment for Minimally-Invasive Urinary Incontinence

LJUBLJANA, Slovenia, 21-Sep-2018 — /EuropaWire/ — The latest study published in the World Journal of Urology (Comparison between erbium‑doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed urinary incontinence – https://doi.org/10.1007/s00345-018-2445-x) provides further … Read the full press release

Sandoz: EMA Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for marketing authorization of infliximab

Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on comprehensive clinical and non-clinical data that is expected to confirm that Sandoz biosimilar infliximab … Read the full press release

Novartis’s omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with severe form of chronic skin disease CSU

Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU)[1] Omalizumab found to be effective, safe and well tolerated in refractory CSU patients, including those on antihistamines at up to four … Read the full press release